Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “ReveraGen BioPharma, Inc.”

15 pharma patents match "ReveraGen BioPharma, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 15
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 15 pharmaceutical patents matching "ReveraGen BioPharma, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

15 results for “ReveraGen BioPharma, Inc.” · 30,257 patents in full index Clear search

  1. US 12201639

    Aqueous oral pharmaceutical suspension compositions

    ReveraGen BioPharma, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  2. US 11833159

    Non-hormonal steroid modulators of NF-kB for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  3. US 11690853

    Non-hormonal steroid modulators of NF-κβ for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  4. US 11471471

    Aqueous oral pharmaceutical suspension compositions

    ReveraGen BioPharma, Inc. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  5. US 11382922

    Aqueous oral pharmaceutical suspension compositions

    ReveraGen BioPharma, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  6. US 10857161

    Non-hormonal steroid modulators of NF-kB for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  7. US 10799514

    Non-hormonal steroid modulators of NF-kappa beta for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted
  8. US 10464967

    Non-hormonal steroid modulators of NF-κβ for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  9. US 10206933

    Non-hormonal steroid modulators of NF-kB for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Feb 19, 2019 · Expires Feb 14, 2039

    granted
  10. US 10000525

    Non-hormonal steroid modulators of NF-κB for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Jun 19, 2018 · Expires Jun 14, 2038

    granted
  11. US 9649320

    Non-hormonal steroid modulators of NF-κB for treatment of disease

    ReveraGen BioPharma, Inc. · Granted May 16, 2017 · Expires May 11, 2037

    granted
  12. US 9637738

    Methods and agents to increase therapeutic dystrophin expression in muscle

    ReveraGen BioPharma, Inc. · Granted May 2, 2017 · Expires Apr 27, 2037

    granted
  13. US 9434758

    Non-hormonal steroid modulators of NF-κB for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Sep 6, 2016 · Expires Sep 1, 2036

    granted
  14. US 9198921

    Non-hormonal steroid modulators of NF-κB for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Dec 1, 2015 · Expires Nov 26, 2035

    granted
  15. US 8673887

    Non-hormonal steroid modulators of NF-kB for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Mar 18, 2014 · Expires Mar 13, 2034

    granted